Cargando…

Two primary cancers appeared after discontinuation of nivolumab in the course of treating Hodgkin lymphoma: a case report

BACKGROUND: Nivolumab is a human monoclonal antibody against programmed death-1 (PD-1) that blocks interactions of PD-1 with both PD-L1 and PD-L2 and upregulates tumor antigen-specific T cell to develop appropriate immune response against cancer cells. It has been approved by the US Food and Drug Ad...

Descripción completa

Detalles Bibliográficos
Autores principales:	Potluri, Lakshmi Bhavani, Nanjareddy, Sushmitha, Al Sbihi, Ali, Manasrah, Nouraldeen, Smith, William, Sano, Dahlia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10364003/ https://www.ncbi.nlm.nih.gov/pubmed/37492791 http://dx.doi.org/10.21037/acr-22-87

Ejemplares similares

Can Lenalidomide Protect against Severe COVID-19 Symptoms in Multiple Myeloma Patients? A Case Series and Review of the Literature
por: Al Sbihi, Ali, et al.
Publicado: (2022)

An HIV Associated Plasmablastic Lymphoma With Spontaneous Tumor Lysis Syndrome
por: Al Sbihi, Ali F, et al.
Publicado: (2020)

P060: Prognosis of patients with relapsed and refractory classic Hodgkin lymphoma after nivolumab discontinuation and efficacy of nivolumab retreatment
por: Fedorova, Liudmila, et al.
Publicado: (2022)

Coronavirus Disease 2019-Associated Bilateral Massive Pulmonary Emboli Caused Death in a Healthy 35-Year-Old Patient
por: Al Sbihi, Ali F, et al.
Publicado: (2020)

Coronary Vasospasm After Dobutamine Stress Echocardiogram Triggered by Esmolol
por: Manasrah, Nouraldeen, et al.
Publicado: (2020)

Isolated Native Tricuspid Valve Endocarditis in an HIV Patient due to Streptococcus Pneumoniae: A Rare Clinical Phenomenon
por: Manasrah, Nouraldeen, et al.
Publicado: (2020)

Gross Hematuria in an Elderly Smoker Male Due to Eosinophilic Cystitis
por: Al Sbihi, Ali F, et al.
Publicado: (2020)

Spontaneous Coronary Artery Dissection: Case Series and Literature Review
por: Manasrah, Nouraldeen, et al.
Publicado: (2021)

Recurrent Spontaneous Pneumothorax Associated With Marijuana Abuse: Case Report and Literature Review
por: Manasrah, Nouraldeen, et al.
Publicado: (2021)

Silent Sigmoid Colon Diverticular Perforation: A Case Report
por: Bashar, Sifullah, et al.
Publicado: (2021)

Early Radiation-Induced Sarcoma in an Adolescent Treated for Relapsed Hodgkin Lymphoma with Nivolumab
por: Šalaševičius, Lukas, et al.
Publicado: (2020)

A Thoracic Endometriosis-Related Catamenial Hemopneumothorax in a Woman With Premature Ovarian Failure
por: Kalbi, Deepak P, et al.
Publicado: (2021)

Severe Insulin Resistance in a Patient Treated With Nivolumab and Brentuximab-Vedotin for Hodgkin Lymphoma
por: Tama, Elif, et al.
Publicado: (2023)

A Paraneoplastic Leukemoid Reaction in Primary Lung Sarcoma
por: Al Sbihi, Ali F, et al.
Publicado: (2021)

Phentermine-Associated Atrial Fibrillation: A Case Report and Literature Review
por: Manasrah, Nouraldeen, et al.
Publicado: (2022)

Real-World Healthcare Resource Utilization in Patients with Classical Hodgkin Lymphoma Treated with Pembrolizumab and Nivolumab in the USA
por: Laliberté, François, et al.
Publicado: (2020)

Nivolumab induced myxedema crisis
por: Khan, Uqba, et al.
Publicado: (2017)

Emerging treatment options for the management of Hodgkin’s lymphoma: clinical utility of nivolumab
por: Bond, David A, et al.
Publicado: (2017)

Hodgkin Lymphoma on Hemodialysis Successfully Treated with Extended Courses of Brentuximab Vedotin
por: Uchimura, Ayana, et al.
Publicado: (2022)

FDA Approval Summary: Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin Lymphoma
por: Kasamon, Yvette L., et al.
Publicado: (2017)

Nivolumab for Methotrexate-associated Classic Hodgkin's Lymphoma in a Rheumatoid Arthritis Patient
por: Tanaka, Keisuke, et al.
Publicado: (2019)

Left Ventricular Thrombus Formation in a Structurally and Functionally Normal Heart: A Case Report and Literature Review
por: Manasrah, Nouraldeen, et al.
Publicado: (2022)

Repeated courses of escalating doses of Nivolumab in refractory Hodgkin lymphoma with recurrent relapses post allografting: A safe and effective treatment approach
por: Kaloyannidis, Panayotis, et al.
Publicado: (2021)

Durable Remission in Hodgkin Lymphoma Treated With One Cycle of Bleomycin, Vinblastine, Dacarbazine and Two Doses of Nivolumab and Brentuximab Vedotin
por: Yohannan, Binoy, et al.
Publicado: (2022)

A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin Lymphoma After Nivolumab Monotherapy Failure
por: Lepik, Kirill V., et al.
Publicado: (2020)

Efficacy and safety of nivolumab combined with brentuximab vedotin after nivolumab monotherapy failure in patients with relapsed and refractory classic Hodgkin lymphoma
por: Fedorova, Liudmila V., et al.
Publicado: (2021)

Efficacy of Brentuximab Vedotin and Nivolumab in Refractory or Relapsed Hodgkin Lymphoma: A Systematic Review
por: Macapagal, Sharina C, et al.
Publicado: (2022)

Correlation of surface receptors with histological appearance in 29 cases of non-Hodgkin lymphoma.
por: Habeshaw, J. A., et al.
Publicado: (1977)

Multicenter phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma
por: Maruyama, Dai, et al.
Publicado: (2017)

A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin’s Lymphoma
por: Hanel, Walter, et al.
Publicado: (2023)

Correction Notice: A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin Lymphoma After Nivolumab Monotherapy Failure
Publicado: (2021)

Transition of the PD-1 occupancy of nivolumab on T cells after discontinuation and response of nivolumab re-challenge
por: Nose, Taku, et al.
Publicado: (2022)

Primary non-Hodgkin’s lymphoma of the mandible
por: Dinakar, J, et al.
Publicado: (2010)

Tumor-associated antigen–specific T cells with nivolumab are safe and persist in vivo in relapsed/refractory Hodgkin lymphoma
por: Dave, Hema, et al.
Publicado: (2022)

Demyelinating polyneuropathy combined with brachial plexopathy after nivolumab therapy for hodgkin lymphoma: a case report
por: Park, Chulmin, et al.
Publicado: (2023)

Nivolumab and brentuximab vedotin with or without bendamustine for R/R Hodgkin lymphoma in children, adolescents, and young adults
por: Harker-Murray, Paul, et al.
Publicado: (2023)

IMMU-19. NIVOLUMAB-INDUCED CNS DEMYELINATION IN A 15-YEAR-OLD WITH CLASSIC HODGKIN LYMPHOMA
por: Ramirez, Alejandra, et al.
Publicado: (2023)

Body mass index is not associated with survival outcomes and immune-related adverse events in patients with Hodgkin lymphoma treated with the immune checkpoint inhibitor nivolumab
por: De Filippi, Rosaria, et al.
Publicado: (2021)

The Value of Screening for Bicuspid Aortic Valve in First Degree Family Members
por: Kandah, Emad, et al.
Publicado: (2021)

Light Chain (AL) Cardiac Amyloidosis: A Diagnostic Dilemma
por: Abdelazeem, Basel, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8mu33o9cso46thpborn9ja0vai